Infections

All Conditions

Neoplasms

Symptoms and General Pathology

Digestive System Diseases

Rare Diseases

Carcinoma

Communicable Diseases

Carcinoma, Hepatocellular

Hepatitis A

Hepatitis C

Hepatitis

Liver Neoplasms

Hepatitis, Chronic

Virus Diseases

Hepatitis C, Chronic

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Liver Diseases

Gastrointestinal Diseases

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Blood-Borne Infections

Hepatitis, Viral, Human

Flaviviridae Infections

RNA Virus Infections

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Bevacizumab

Atezolizumab

Antibodies

Antibodies, Monoclonal

Immunomodulating Agents

Immunoglobulins

Sofosbuvir

Velpatasvir

Antiviral Agents

Ribavirin

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Antimetabolites

Immune Checkpoint Inhibitors

Participants will receive bevacizumab and atezolizumab about every 3 weeks as part of the standard of care HCC treatment that is managed by your cancer doctor. In addition, Participants will continue receiving your standard of care DAAs (either sofosbuvir + velpatasvir or sofosbuvir + velpatasvir + voxilaprevir)

Voxilaprevir

Harrys A Torres, MD

Harrys A. Torres, MD

To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.

Primary Objective(s):

* Estimate the objective response rate (ORR) to ICT and estimate the sustained virologic response (SVR) in patients with HCC and chronic HCV infection using HCV clearance with DAA therapy.
* Estimate the change of the overall T cells and virus-specific T cells before and after the antiviral treatment in patients with HCC and chronic HCV infection using HCV clearance with DAA therapy.

Secondary objective:

--Collect the safety profile of the treatment and estimate the time-to-event variable such as overall survival (OS) and progression free survival (PFS).

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

National Cancer Institute (NCI)

M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for voxilaprevir

Every month we try and update this database with for voxilaprevir cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.